Clinical evaluation of glucagon and insulin in therapy of fulminant hepatitis
- 19 Downloads
Fulminant hepatitis (FH) is defined as a clinical syndrome that develops as a result of massive necrosis of liver cells followed by severe impairment of hepatic function due to viral infection or drugs, in a patient in whom there has been no previous evidence of liver disease. The mortality rate of this condition is extremely high1–3. A nationwide survey conducted in Japan comprising the period 1974–1976, when steroid hormone and/or blood exchange was believed to be useful, revealed a 16.5% survival in FH cases4.
KeywordsHepatic Encephalopathy Fulminant Hepatic Failure Fulminant Hepatitis Blood Exchange Liver Cell Necrosis
Unable to display preview. Download preview PDF.
- 2.Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, eds. Progress in Liver Disease, 3rd edn. New York: Grune & Stratton, 1970: 282–298.Google Scholar
- 3.Karvoutzis GG, Redeker AG, Peters RL. Long-term follow-up studies on patients surviving fulminant viral hepatitis. Gastroenterology 1974; 67: 870–877.Google Scholar
- 4.Takahashi Y, Shimizu M, Kosaka M. Nation-wide statistics of fulminant hepatitis (Jap). Saishin Igaku 1979; 34: 2285–2292.Google Scholar
- 8.Caruana J A, Goldman JK, Camara DS, Gage AA. Insulin, glucagon and glucose in the regeneration response of the liver. Surg Gynecol Obstet 1981; 153: 726–730.Google Scholar
- 16.Takahashi Z. Annual report of nation-wide statistics of fulminant hepatitis — 1982, 1983, 1985. (Supported by a Grant-in-Aid from the Japanese Ministry of Health and Welfare.) Personal communication, 1985.Google Scholar